- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04574635
Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer
Study Overview
Status
Conditions
- Cervical Adenosquamous Carcinoma
- Cervical Squamous Cell Carcinoma, Not Otherwise Specified
- Recurrent Cervical Carcinoma
- Stage IB3 Cervical Cancer FIGO 2018
- Stage II Cervical Cancer FIGO 2018
- Stage IIA Cervical Cancer FIGO 2018
- Stage IIA1 Cervical Cancer FIGO 2018
- Stage IIA2 Cervical Cancer FIGO 2018
- Stage IIB Cervical Cancer FIGO 2018
- Stage III Cervical Cancer FIGO 2018
- Stage IIIA Cervical Cancer FIGO 2018
- Stage IIIB Cervical Cancer FIGO 2018
- Stage IIIC Cervical Cancer FIGO 2018
- Stage IIIC1 Cervical Cancer FIGO 2018
- Stage IIIC2 Cervical Cancer FIGO 2018
- Stage IVA Cervical Cancer FIGO 2018
- Stage IB1 Cervical Cancer AJCC v8
- Metastatic Cervical Carcinoma
- Infiltrating Cervical Carcinoma
- Stage I Cervical Cancer FIGO 2018
- Stage IA Cervical Cancer FIGO 2018
- Stage IA1 Cervical Cancer FIGO 2018
- Stage IA2 Cervical Cancer FIGO 2018
- Stage IB Cervical Cancer FIGO 2018
- Stage IB2 Cervical Cancer FIGO 2018
- Stage IV Cervical Cancer FIGO 2018
- Stage IVB Cervical Cancer FIGO 2018
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To estimate the ctDNA detection rate in cervix cancer patients undergoing surgery, radiotherapy, chemotherapy, and/or immunotherapy in the setting of primary, recurrent or metastatic disease.
II. Association of ctDNA baseline levels and clearance kinetics with clinical and radiographic tumor response.
III. To explore the association of detectable ctDNA at each time point with invasive recurrence-free survival and overall survival.
IV. To explore the use of ctDNA for surveillance and detection of disease recurrence.
V. To create a repository for future exploratory studies including analyzing changes in T cell and other immune cell subpopulations during and following therapy for cervix cancer.
OUTLINE: Patients are assigned to 1 of 4 cohorts.
COHORT 1: Patients undergo collection of blood samples at baseline prior to surgery, at 6 weeks, 3, 6, and 12 months post-surgery, every 6 months during year 2, and at the time of recurrence (if applicable).
COHORT 2: Patients undergo collection of blood samples at baseline prior to the first fraction of radiation, during week 4 of radiotherapy, at 6 weeks, 3, 6, and 12 months post-radiotherapy, every 6 months during year 2, and at the time of recurrence (if applicable).
COHORT 3: Patients undergo collection of blood samples at baseline prior to the first fraction of radiation, during week 4 of radiotherapy, on the day of the final fraction of radiotherapy, at 3 months post-radiotherapy, every 3 months during years 1 and 2, and at the time of recurrence (if applicable).
COHORT 4: Patients undergo collection of blood samples at baseline prior to initiation of chemotherapy or immunotherapy, at 4 weeks and 8 weeks after initiation of chemotherapy or immunotherapy, every 3 months during years 1 and 2, and at the time of recurrence (if applicable).
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic in Rochester
-
Contact:
- Clinical Trials Referral Office
- Phone Number: 855-776-0015
- Email: mayocliniccancerstudies@mayo.edu
-
Principal Investigator:
- Allison E. Garda, M.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Able to provide written consent
- Patient has given permission to give tumor/blood sample for research testing
- Histological confirmation of squamous cell carcinoma or adenosquamous carcinoma
- Known HPV status defined as positive staining for p16 on immunohistochemistry (IHC) or DNA in situ hybridization (ISH) for HPV
- Willingness to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)
- Consent to allow blood specimens to be shared with potential external collaborators
Cohort #1: Surgery alone for early stage disease (Federation of Gynecology and Obstetrics [FIGO] stage IA-IB1)
- FIGO 2019 stage IA1, IA2, IB1
- Plan to undergo surgery including but not limited to trachelectomy, radical hysterectomy, and lymph node dissection
Cohort #2: Post-operative radiation +/- chemotherapy for intermediate and high risk factors
- Any FIGO stage
Status post any definitive surgical procedure (e.g. radical hysterectomy and lymph node dissection) and on final pathology found to have risk factors:
- Intermediate risk: Lymphovascular space invasion (LVSI), deep cervical stromal invasion, tumor size > 4 cm
- High risk: pelvic or para-aortic lymph nodes, parametrial invasion, positive surgical margins
- Plan to undergo pelvic +/- para-aortic radiotherapy with or without chemotherapy per standard of care
Cohort #3: Definitive chemoradiotherapy for locally advanced disease (FIGO stage IB2-IIIC)
- FIGO 2019 Stage IB2-IIIC or not a surgical candidate
- Plan to undergo definitive chemoradiotherapy including external beam radiotherapy, brachytherapy, and chemotherapy
Cohort #4: Systemic treatment for recurrent or metastatic disease
- Any recurrence (local, regional, or distant) after prior treatment for cervical cancer
- Metastases at first diagnosis without prior treatment
Exclusion Criteria:
Other active malignancy =< 2 years prior to registration.
- EXCEPTIONS: Non-melanotic skin cancer
- NOTE: If there is a history or prior malignancy, they must not be receiving other specific treatment for cancer
- Pregnancy or lactation
- Inability on the part of the patient to understand the informed consent to be compliant with the protocol
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Cohort 1 (surgery patients)
Patients undergo collection of blood samples at baseline prior to surgery, at 6 weeks, 3, 6, and 12 months post-surgery, every 6 months during year 2, and at the time of recurrence (if applicable).
|
Undergo collection of blood samples
|
Cohort 2 (post-operative radiation +/- chemotherapy patients)
Patients undergo collection of blood samples at baseline prior to the first fraction of radiation, during week 4 of radiotherapy, at 6 weeks, 3, 6, and 12 months post-radiotherapy, every 6 months during year 2, and at the time of recurrence (if applicable).
|
Undergo collection of blood samples
|
Cohort 3 (definitive chemoradiotherapy patients)
Patients undergo collection of blood samples at baseline prior to the first fraction of radiation, during week 4 of radiotherapy, on the day of the final fraction of radiotherapy, at 3 months post-radiotherapy, every 3 months during years 1 and 2, and at the time of recurrence (if applicable).
|
Undergo collection of blood samples
|
Cohort 4 (systemic treatment patients)
Patients undergo collection of blood samples at baseline prior to initiation of chemotherapy or immunotherapy, at 4 weeks and 8 weeks after initiation of chemotherapy or immunotherapy, every 3 months during years 1 and 2, and at the time of recurrence (if applicable).
|
Undergo collection of blood samples
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients with undetectable circulating tumor deoxyribonucleic acid (ctDNA) posttreatment in patients with detectable ctDNA pre-treatment
Time Frame: At 6 weeks post-surgery (cohort 1), at 4-6 weeks after completion of chemotherapy and radiation (cohort 2), 4-6 weeks post End of chemotherapy and radiotherapy (cohort 3), at 8 weeks after start of chemotherapy or immunotherapy (cohort 4)
|
The proportion will be reported along with the exact 95% binomial confidence interval.
Additionally will report the mean standard deviation and median interquartile range ctDNA post-treatment in these patients.
|
At 6 weeks post-surgery (cohort 1), at 4-6 weeks after completion of chemotherapy and radiation (cohort 2), 4-6 weeks post End of chemotherapy and radiotherapy (cohort 3), at 8 weeks after start of chemotherapy or immunotherapy (cohort 4)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ctDNA levels
Time Frame: Baseline
|
Will be associated with Federation of Gynecology and Obstetrics stage and assessed using linear regression, reporting the correlation as well as the model estimates.
|
Baseline
|
Clinical tumor response
Time Frame: At post-treatment assessment, assessed up to 2 years
|
Will be assessed for association with baseline and post-treatment ctDNA using logistic regression.
Depending on the number of tumor response, or non-response patients whichever is fewer, multiple variable models may be considered including additional relevant baseline covariates such as disease stage.
|
At post-treatment assessment, assessed up to 2 years
|
Radiographic tumor response
Time Frame: At post-treatment assessment, assessed up to 2 years
|
Will be assessed for association with baseline and post-treatment ctDNA using logistic regression.
Depending on the number of tumor response, or non-response patients whichever is fewer, multiple variable models may be considered including additional relevant baseline covariates such as disease stage.
|
At post-treatment assessment, assessed up to 2 years
|
Recurrence-free survival
Time Frame: Up to 2 years
|
Baseline ctDNA and ctDNA at measured time points will be considered in Cox models.
|
Up to 2 years
|
Overall survival
Time Frame: Up to 2 years
|
Baseline ctDNA and ctDNA at measured time points will be considered in Cox models.
ctDNA other than at baseline will be considered in these models as a time dependent covariate.
Depending on the number of events, multiple variable models may be considered including additional relevant baseline covariates such as disease stage.
|
Up to 2 years
|
ctDNA clearance kinetics
Time Frame: Up to 2 years
|
Will be correlated with recurrence-free survival.
ctDNA other than at baseline will be considered in these models as a time dependent covariate.
Depending on the number of events, multiple variable models may be considered including additional relevant baseline covariates such as disease stage.
|
Up to 2 years
|
ctDNA conversion
Time Frame: Up to 2 years
|
Will be correlated during the active monitoring phase with recurrence-free survival.
|
Up to 2 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Allison E. Garda, M.D., Mayo Clinic in Rochester
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Uterine Neoplasms
- Genital Neoplasms, Female
- Uterine Cervical Diseases
- Uterine Diseases
- Neoplasms, Complex and Mixed
- Neoplasms, Squamous Cell
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Uterine Cervical Neoplasms
- Carcinoma
- Carcinoma, Squamous Cell
- Carcinoma, Adenosquamous
- Papilloma
Other Study ID Numbers
- ROR1905 (Other Identifier: Mayo Clinic in Rochester)
- NCI-2020-06965 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- 19-011924 (Other Identifier: Mayo Clinic Institutional Review Board)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cervical Adenosquamous Carcinoma
-
UNC Lineberger Comprehensive Cancer CenterCompletedCervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma | Cervix CarcinomaUnited States
-
National Cancer Institute (NCI)TerminatedCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Carcinoma | Cervical Carcinoma, Non-SquamousTypeUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma | Recurrent Cervical Carcinoma | Stage IVB Cervical CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)TerminatedLymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1 Cervical CancerCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma | Stage I Cervical CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Recurrent Cervical CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Recurrent Cervical Cancer | Stage IVB Cervical Cancer | Cervical Adenosquamous Cell CarcinomaCanada
-
National Cancer Institute (NCI)Gynecologic Oncology Group; NCIC Clinical Trials GroupTerminatedCervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer | Cervical Adenosquamous Cell CarcinomaUnited States, Canada
-
National Cancer Institute (NCI)CompletedOxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical CancerCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma | Recurrent Cervical Carcinoma | Stage IVA Cervical Cancer | Stage IVB Cervical CancerUnited States
-
National Cancer Institute (NCI)NRG OncologyCompletedCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma | Recurrent Cervical Carcinoma | Stage IVB Cervical CancerUnited States, Spain
-
Gynecologic Oncology GroupNational Cancer Institute (NCI); Advaxis, Inc.CompletedCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Recurrent Cervical CarcinomaUnited States
Clinical Trials on Biospecimen Collection
-
LLS PedAL Initiative, LLCNational Cancer Institute (NCI); Children's Oncology GroupRecruitingAcute Myeloid Leukemia | Juvenile Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome | Myeloid Leukemia Associated With Down Syndrome | Mixed Phenotype Acute Leukemia | Acute Myeloid Leukemia Post Cytotoxic Therapy | Myelodysplastic Syndrome Post Cytotoxic TherapyUnited States, Canada, Australia, Puerto Rico, New Zealand
-
Thomas Jefferson UniversityNational Cancer Institute (NCI)Active, not recruiting
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingMetastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8United States
-
Ohio State University Comprehensive Cancer CenterGuardant Health, Inc.RecruitingColorectal CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Recruiting
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingBreast Adenocarcinoma | HER2-Positive Breast CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingAnatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditionsUnited States, Puerto Rico
-
University of MichiganRecruitingFocal Segmental Glomerulosclerosis | Minimal Change Disease | FSGS | MCDUnited States
-
Thomas Jefferson UniversityRecruitingMalignant Solid Neoplasm | GlioblastomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); National Institute of General Medical Sciences...Recruiting